Drug Development and Regulation

Pharmacology

Your browser is too old

We can't provide a great video experience on old browser

Update now
Fuzbjvls1usixc2zb7ht 180625 s0 arfeen zain drug development and regulation intro
04:27
Drug Development and Regulation
Zg7brgausskooa47tr3v 180625 s1 arfeen zain drug discovery and development
13:29
Drug Discovery and Development
4ymmv8vzrvoucjvbffme 180625 s2 arfeen zain drug screening
16:56
Drug Screening
3eeexswrauhjlpez1c94 180625 s3 arfeen zain preclinical safety and toxicity testing
10:35
Preclinical Safety and Toxicity Testing
Igkyokkqfy2mrkdxnnsa 180625 s4 arfeen zain confounding factors in clinical trials and fda
15:09
Confounding Factors in Clinical Trials and FDA
Eisjm2ofqog83cwukb6p 180625 s5 arfeen zain clinical trials the ind and nda
13:06
Clinical Trials: The IND and NDA

Lecture´s Description

Drug Discovery and Development

In this lecture ´´Drug Development and Regulation´´ is explained. Section one is about ´´Drug Discovery and Development ´´. Educator tells about the beginning of a new drug. In the next slide new drug development is discussed. After that drug discovery is explained.

Drug Screening

Section two is about ‘’Drug Screening’’. At first educator introduces drug screening. Then selection of compound is discussed. After that identification of mechanism of action is pursued. In the next slide drug evaluation in animal models is focused. Additionally, information is conveyed on compound/lead optimization. In the last slide integrated drug discovery is reported.

Preclinical Safety and Toxicity Testing

Section three is about ‘’Preclinical Safety and Toxicity Testing’’. Educator tells that the dose makes the poison. Then information about safety tests is given. Moreover, goals of preclinical toxicity are discussed. At the end of this section limitations of preclinical testing is explained.

Confounding Factors in Clinical Trials and FDA

Section four is about ‘’Confounding Factors in Clinical Trials and FDA’’. Initially, the variable natural history of most diseases is covered. Next, the presence of other diseases and risk factors is discussed. After that subject and observer bias and other factors is explained. Educator tells that how to avoid subjects bias. Moreover, how to avoid observer bias is also highlighted.

Clinical Trials: The IND and NDA

Section five is about ‘’Clinical Trials: The IND and NDA’’. Primary emphasis is on investigational exemption for a new drug (IND). In the next slide phases of clinical trials are illustrated. Moving onward conflicts of interest are also focused. After that adverse drug reactions are described. Last part of this section includes the discussion of orphan drugs and treatment of rare diseases.

Studies have shown that V-Learning™ increases student's learning and passing rate Significantly.

100% satisfaction guaranteed, join us & boost your medical Knowledge